Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

References

• LjungbergBAlbigesLBensalahKEuropean Association of Urology guidelines on renal cell carcinoma2017 Available from: http://uroweb.org/guideline/renal-cell-carcinomaAccessed April 20, 2017
   Google Scholar
• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 34956
   Web of Science ®Google Scholar
• RiniBICampbellSCEscudierBRenal cell carcinomaLancet200937396691119113219269025
   PubMed Web of Science ®Google Scholar
• LamJSLeppertJTBelldegrunASFiglinRANovel approaches in the therapy of metastatic renal cell carcinomaWorld J Urol200523320221215812574
   PubMed Web of Science ®Google Scholar
• ChoueiriTKMotzerRJSystemic therapy for metastatic renal-cell carcinomaN Engl J Med2017376435436628121507
   PubMed Web of Science ®Google Scholar
• ButiSLeonettiADallatomasinaABersanelliMEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyCore Evid201611233627621699
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• SloanBScheinfeldNSPazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapyCurr Opin Investig Drugs200891213241335
   PubMed Web of Science ®Google Scholar
• Hu-LoweDDZouHYGrazziniMLNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res200814227272728319010843
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• ChoueiriTKEscudierBJPowlesTCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialLancet Oncol201617791792727279544
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFCheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology: kidney cancer (version 2.2017) Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdfAccessed May 20, 2017
   Google Scholar
• BanumathyGCairnsPSignaling pathways in renal cell carcinomaCancer Biol Ther201010765866420814228
   PubMed Web of Science ®Google Scholar
• HickeyMMSimonMCRegulation of angiogenesis by hypoxia and hypoxia-inducible factorsCurr Top Dev Biol20067621725717118268
   PubMed Web of Science ®Google Scholar
• GudasLJFuLMintonDRMonganNPNanusDMThe role of HIF1α in renal cell carcinoma tumorigenesisJ Mol Med (Berl)201492882583624916472
   PubMed Web of Science ®Google Scholar
• KatsoROkkenhaugKAhmadiKWhiteSTimmsJWaterfieldMDCellular function of phosphoinositide 3-kinases: implications for development, immunity, homeostasis, and cancerAnnu Rev Cell Dev Biol20011761567511687500
   PubMed Web of Science ®Google Scholar
• BernardiRGuernahIJinDPML inhibits HIF-1α translation and neoangiogenesis through repression of mTORNature2006442710477978516915281
   PubMed Web of Science ®Google Scholar
• ToschiALeeEGadirNOhhMFosterDADifferential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2J Biol Chem200828350344953449918945681
   PubMed Web of Science ®Google Scholar
• GuoHGermanPBaiSThe PI3K/AKT pathway and renal cell carcinomaJ Genet Genomics201542734335326233890
   PubMed Web of Science ®Google Scholar
• RavaudABarriosCHAlekseevBRECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaAnn Oncol20152671378138425851632
   PubMed Web of Science ®Google Scholar
• FlahertyKTManolaJBPinsMBEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma – a trial of the ECOG-ACRIN Cancer Research Group (E2804)J Clin Oncol201533212384239126077237
   PubMed Web of Science ®Google Scholar
• RiniBBellmuntJClancyJRandomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trialJ Clin Oncol201432875275924297945
   PubMed Web of Science ®Google Scholar
• OkamotoKKodamaKTakaseKAntitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsCancer Lett201334019710323856031
   PubMed Web of Science ®Google Scholar
• SonpavdeGWilleyCDSudarshanSFibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinomaExpert Opin Investig Drugs2014233305315
   PubMed Web of Science ®Google Scholar
• MatsukiMAdachiYOzawaYTargeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimusCancer Sci2017108476377128107584
   PubMed Web of Science ®Google Scholar
• YamadaKYamamotoNYamadaYPhase I dose–escalation study and biomarker analysis of E7080 in patients with advanced solid tumorsClin Cancer Res20111782528253721372218
   PubMed Web of Science ®Google Scholar
• BossDSGlenHBeijnenJHA phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBr J Cancer2012106101598160422516948
   PubMed Web of Science ®Google Scholar
• GuptaAJarzabBCapdevilaJShumakerRHusseinZPopulation pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancerBr J Clin Pharmacol20168161124113326879594
   PubMed Web of Science ®Google Scholar
• DubbelmanACRosingHNijenhuisCPharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomasInvest New Drugs201533123324025377392
   PubMed Web of Science ®Google Scholar
• HusseinZMizuoHHayatoSNamikiMShumakerRClinical pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitorEur J Drug Metab Pharmacokinet Epub2017224
   PubMed Web of Science ®Google Scholar
• ShumakerRCAluriJFanJMartinezGThompsonGARenMEffect of rifampicin on the pharmacokinetics of lenvatinib in healthy adultsClin Drug Investig2014349651659
   PubMed Web of Science ®Google Scholar
• ShumakerRAluriJFanJMartinezGThompsonGARenMEffects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participantsClin Pharmacol Drug Dev20154215516026097795
   PubMed Web of Science ®Google Scholar
• ShumakerRAluriJFanJMartinezGPentikisHRenMInfluence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administrationJ Clin Pharmacol201555331732725204557
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTEGlenHLenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open-label, multicenter trialLancet Oncol2015161473148226482279
   PubMed Web of Science ®Google Scholar
• MolinaAMHutsonTELarkinJA phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Cancer Chemother Pharmacol201473118118924190702
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTERenMDutcusCLarkinJIndependent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinomaLancet Oncol2016171e4e526758760
   PubMed Web of Science ®Google Scholar
• EISAIEisai submits new application in Europe for in-house developed anticancer agent lenvatinib seeking approval for indication covering renal cell carcinoma Available from: www.eisai.com/news/news201602.htmlAccessed April 20, 2017
   Google Scholar
• MotzerRJEscudierBOudardSRECORD-1 Study GroupEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• ButiSBersanelliMCombination therapy in kidney cancer: the next revolution?Lancet Oncol201516151441144226482275
   PubMed Web of Science ®Google Scholar
• Eisai IncLenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT02811861. NLM identifier: NCT02811861Accessed April 20, 2017
   Google Scholar
• Eisai IncA Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease Available from: https://clinicaltrials.gov/ct2/show/NCT02915783. NLM identifier: NCT02915783Accessed April 20, 2017
   Google Scholar